trending Market Intelligence /marketintelligence/en/news-insights/trending/5SrPUGCXuQ7QctjBpxVQZg2 content esgSubNav
In This List

ImmunoCellular CEO resigns

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

ImmunoCellular CEO resigns

ImmunoCellular Therapeutics Ltd. CEO Andrew Gengos is resigning, though he will remain on the board.

The company appointed Anthony Gringeri to replace him.

Gringeri has been working at ImmunoCellular as senior vice president of strategic resources since August 2013.

The company said the change reflects its strategy to focus on the ICT-107 program, a dendritic-cell based immunotherapy that targets brain cancer stem cells.